FDA Rebuffs AstraZeneca's Bid To Delay Generic Seroquel
The U.S. Food and Drug Administration has rejected AstraZeneca PLC's bid to delay the launch of generic versions of the U.K.-based pharmaceutical giant's blockbuster anti-psychotic drug Seroquel, the company said Friday....To view the full article, register now.
Already a subscriber? Click here to view full article